

REMARKS

A. Election of Group

The Office sets forth a restriction requirement for the following groups of claims:

Group I (Claims 1-12 and 23-38) is drawn to an antisense molecule targeted to a splice acceptor site in human c-myc mRNA and methods of inhibiting using the antisense;

Group II (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in myb mRNA and methods of inhibiting using the antisense;

Group III (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in rel mRNA and methods of inhibiting using the antisense;

Group IV (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in fos mRNA and methods of inhibiting using the antisense;

Group V (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in jun mRNA and methods of inhibiting using the antisense;

Group VI (Claims 1-7, 19, 20, 23-33, 37 and 38) is drawn to an antisense molecule targeted to a splice acceptor site in human abl mRNA and methods of inhibiting using the antisense;

Group VII (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in bcl mRNA and methods of inhibiting using the antisense;

Group VIII (Claims 1-7, 17, 18, 23-33, 37 and 38) is drawn to an antisense molecule targeted to a splice acceptor site in human p53, mRNA and methods of inhibiting using the antisense;

Group IX (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in a cathedrin mRNA and methods of inhibiting using the antisense;

Group X (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in a cathedrin mRNA and methods of inhibiting using the antisense;

Group XI (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in a telomerase mRNA and methods of inhibiting using the antisense;

Group XII (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in a cytokine mRNA and methods of inhibiting using the antisense;

Group XIII (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in a kinase mRNA and methods of inhibiting using the antisense;

Group XIV (Claims 1-7, 13, 14, 23-33, 37 and 38) is drawn to an antisense molecule targeted to a splice acceptor site in human androgen receptor mRNA and methods of inhibiting using the antisense;

Group XV (Claims 1-7, 15, 16, 23-33, 37 and 38) is drawn to an antisense molecule targeted to a splice acceptor site in hCG β subunit mRNA and methods of inhibiting using the antisense;

Group XVI (Claims 1-7, 31-33, 37 and 38) is drawn to an antisense molecule targeted to a splice acceptor site in HIV rev mRNA and methods of inhibiting using the antisense;

Group XVII (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in human papilloma virus mRNA and methods of inhibiting using the antisense;

Group XVIII (Claims 1-7 and 23-33) is drawn to an antisense molecule targeted to a splice acceptor site in human parvovirus B19mRNA and methods of inhibiting using the antisense;

The Applicants hereby provisionally elect the claims of Group VIII (Claims 1-7, 17, 18, 23-33, 37 and 38) for examination in the present application.

Nucleotide Sequence Election

The Office has further required the election of one antisense sequence within the elected Group VIII, *i.e.*, the election of SEQ ID NO: 35 or SEQ ID NO: 36. Applicants further provisionally elect SEQ ID NO: 35 with traverse, for examination in the present invention.

Reconsideration is requested of the restriction of one (1) antisense sequence within elected Group VIII. As acknowledged by the Examiner, "the Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of nucleotide sequences to be claimed in a single application. *See MPEP 803.04 and 2434.* Further, under this policy, "[i]t has been determined that normally ten sequences constitute a reasonable number for examination purposes." *See id.* Applicants urge that the examination of two (2) sequences is not considered to be an unreasonable number of sequences for examination in the present invention and the examination of two sequences is not an undue burden, especially in light of the notion that both SEQ ID NO: 35 and SEQ ID NO: 36 target and modulate expression of p53..

For the reasons set forth above, reconsideration of the restriction requirement with regard to the election of one antisense sequence and rejoinder of SEQ ID NO: 36 is

respectfully requested. Applicants reserve the right to file divisional applications directed to the non-elected claims of Groups I-VII and IX-XVIII.

Respectfully submitted,

PERKINS COIE LLP



Karen Y. Hui
Registration No. 44,785

Date: 11-12-2002
PERKINS COIE LLP
P. O. Box 2168
Menlo Park, CA 94026
(650) 838-4300
Customer No. 22918